269 related articles for article (PubMed ID: 12411291)
1. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation.
Lisman T; Moschatsis S; Adelmeijer J; Nieuwenhuis HK; De Groot PG
Blood; 2003 Mar; 101(5):1864-70. PubMed ID: 12411291
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation.
Lisman T; Adelmeijer J; Heijnen HF; de Groot PG
Blood; 2004 Mar; 103(5):1720-7. PubMed ID: 14592825
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
4. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
Lele M; Sajid M; Wajih N; Stouffer GA
Circulation; 2001 Jul; 104(5):582-7. PubMed ID: 11479257
[TBL] [Abstract][Full Text] [Related]
5. Increased local procoagulant action: a mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders.
Galán AM; Tonda R; Pino M; Reverter JC; Ordinas A; Escolar G
Transfusion; 2003 Jul; 43(7):885-92. PubMed ID: 12823748
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb-IIIa and RGD(S) are not important for fibronectin-dependent platelet adhesion under flow conditions.
Nievelstein PF; Sixma JJ
Blood; 1988 Jul; 72(1):82-8. PubMed ID: 2968824
[TBL] [Abstract][Full Text] [Related]
7. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
Lisman T; Adelmeijer J; Cauwenberghs S; Van Pampus EC; Heemskerk JW; De Groot PG
J Thromb Haemost; 2005 Apr; 3(4):742-51. PubMed ID: 15842358
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
Weber AA; Schrör K
Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
[TBL] [Abstract][Full Text] [Related]
10. New Insights Into the Treatment of Glanzmann Thrombasthenia.
Poon MC; Di Minno G; d'Oiron R; Zotz R
Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
13. Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
Levy-Mendelovich S; Levy T; Budnik I; Barg AA; Rosenberg N; Seligsohn U; Kenet G; Livnat T
Thromb Haemost; 2019 Jan; 119(1):117-127. PubMed ID: 30597506
[TBL] [Abstract][Full Text] [Related]
14. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
15. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
[TBL] [Abstract][Full Text] [Related]
16. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
[TBL] [Abstract][Full Text] [Related]
17. Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets.
Ilveskero S; Lassila R
J Thromb Haemost; 2003 Apr; 1(4):805-13. PubMed ID: 12871419
[TBL] [Abstract][Full Text] [Related]
18. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
19. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Lages B; Weiss HJ
Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
[TBL] [Abstract][Full Text] [Related]
20. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
